1. New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer (NYU 10-01969) Objectives: Currently no druggable targets exist for TNBC Clinical outcomes of TNBC may be related to tumor immune responses Evidence exists that RT combined with carboplatin increases tumor cell death, while contributing to a pro-immunogenic melieu 1 We established a phase I-II, prospective/single arm, feasibility study to determine the proportion of patients with grade II-III acute skin toxicities (1° endpoint) 1. Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014; 3: e28518.

2. New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer (NYU 10-01969) Schema:

3. New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer (NYU 10-01969) Results: 27 patients have accrued Median follow-up of 26 months Median age of 56 years All women remain alive without recurrent disease

4. New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer (NYU 10-01969) Conclusions: Adjuvant concurrent carboplatin and prone accelerated radiotherapy is a safe and effective treatment for women with early stage TNBC Since ~50% of TNBC carriers recur within 2 years from treatment, it is encouraging that none of the patients in the trial have experienced a recurrence The trial continues to the planned accrual of 35 patients